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Abstract
Amino acid (AA) metabolism is involved in diverse cellular functions, including cell survival and 
growth, however it remains unclear how it regulates normal hematopoiesis versus leukemogenesis. 
Here, we report that knockout of Slc1a5 (ASCT2), a transporter of neutral AAs, especially 
glutamine, results in mild to moderate defects in bone marrow and mature blood cell development 
under steady state conditions. In contrast, constitutive or induced deletion of Slc1a5 decreases 
leukemia initiation and maintenance driven by the oncogene MLL-AF9 or Pten deficiency. 
Survival of leukemic mice is prolonged following Slc1a5 deletion, and pharmacological inhibition 
of ASCT2 also decreases leukemia development and progression in xenograft models of human 
acute myeloid leukemia. Mechanistically, loss of ASCT2 generates a global effect on cellular 
metabolism, disrupts leucine influx and mTOR signaling, and induces apoptosis in leukemic cells. 
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Given the substantial difference in reliance on ASCT2-mediated AA metabolism between normal 
and malignant blood cells, this in vivo study suggests ASCT2 as a promising therapeutic target for 
the treatment of leukemia.
INTRODUCTION
It has been known for a long time that cellular metabolism is remarkably changed in tumor 
cells as opposed to their normal counterparts. Tumor cells consume glucose at higher rates. 
However, in these highly proliferative cells, oxidation of glucose-derived pyruvate in 
mitochondria is limited and a large portion of pyruvate is diverted to the cytosol for 
fermentation, even in the presence of ample oxygen. This aerobic glycolysis, known as the 
Warburg effect, is a hallmark of cancer cell metabolism 1–4. The Warburg effect helps lower 
production of reactive oxygen species, the byproduct of mitochondrial oxidative 
phosphorylation. In addition, decreased pyruvate oxidation in mitochondria leads to elevated 
upstream glycolytic intermediates, which is beneficial for robust biosynthesis during tumor 
growth. Due to defective pyruvate oxidation in the mitochondria, cancer cells turn to 
alternative fuels such as free fatty acids and amino acids (AAs) to support oxidative 
phosphorylation 3,5.
AAs represent an important class of major nutrients obligatory for cell survival and growth. 
They are not only used as building blocks for synthesis of proteins, nucleotides, and cellular 
primary antioxidant glutathione, but also play essential roles in energy production and 
intermediate metabolism in mitochondria 6,7. Intermediate metabolites produced by the 
tricarboxylic acid (TCA) cycle in mitochondria are utilized for biosynthesis in the cytosol, 
and participate in epigenetic regulation of nuclear gene expression 8,9. In addition, AAs 
serve regulatory roles in governing cell growth, mainly through signaling to the energy, 
nutrient and growth factor integrating kinase mTOR 10,11. Tumor cells have notably 
increased demands for these nutrients to support their exceptionally fast proliferation 6,7. 
Essential AAs must be obtained from external sources through transmembrane transporters. 
Non-essential AAs can be synthesized endogenously, but also need to be obtained from 
external sources if the capacity of endogenous synthesis does not meet the increased 
demands of highly proliferative cells. ASCT2, also known as sodium-dependent solute 
carrier family 1 member 5 (Slc1a5), is a transmembrane transporter that mediates the uptake 
of neutral AAs, including glutamine (Gln), cysteine (Cys), serine (Ser), threonine (Thr), 
valine (Val), alanine (Ala), etc. 12,13. ASCT2 has been found to be expressed at high levels 
in cancer, and knockdown or inhibition of ASCT2 has been shown to decrease cell growth in 
cell lines 14–18. However, the role of ASCT2 in physiology has not been well characterized. 
Whether healthy cells and tumor cells of the same origin have differential responses to loss 
of ASCT2 function in in vivo settings remains to be determined.
The role of ASCT2-mediated AA metabolism in normal and malignant hematopoietic cell 
development is not well understood. We have become interested in ASCT2 because our 
recent gene expression profiling analyses showed that Slc1a5 (ASCT2) along with other 
plasma membrane transporters and metabolic enzymes involved in AA metabolism were 
significantly upregulated in mitochondrial phosphatidylinositol phosphate phosphatase 
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PTPMT1 knockout hematopoietic stem cells (HSCs), in which mitochondrial aerobic 
metabolism was decreased due to impaired utilization of pyruvate while cytosolic glycolysis 
was enhanced 19,20. This apparently adaptive response of Slc1a5 expression in PTPMT1 
knockout HSCs led us to determine the role of ASCT2-mediated AA metabolism in 
hematopoietic cell development. We have found that deletion of ASCT2 had modest effects 
on steady state normal blood cell development, but substantially decreased leukemia 
development and progression in mouse and xenograft models of human acute myeloid 
leukemia (AML).
RESULTS
Deletion of Slc1a5 leads to mild defects in steady state hematopoiesis
Our recent quantitative RT-PCR (qRT-PCR) analyses showed that levels of Slc1a5 (ASCT2) 
in HSCs were ~6-fold higher than those in whole bone marrow (BM) cells (Supplementary 
Fig. 1a). Given that ASCT2 is responsible for the transport of neutral AAs, especially Gln 
13
, we examined the impact of Gln deprivation on HSCs in vitro. Compared to the control 
culture, myeloid (Mac-1+Gr-1+) cells derived from HSCs were drastically decreased in Gln-
free medium, and ~90% of the cells remained at the Lineage− (Lin−) stage even after 14 days 
of culture (Supplementary Fig. 1b). Total cell number was ~20-fold lower than that of the 
control group (Supplementary Fig. 1c). To further determine the function of ASCT2 in 
hematopoietic cell development, we created a Slc1a5 conditional allele (Slc1a5fl) and 
generated global knockout allele (Slc1a5-) by crossing Slc1a5fl/+ mice with CMV-Cre mice 
to delete Slc1a5 from the germline (Supplementary Fig. 2a, b). Depletion of ASCT2 at 
mRNA and protein levels in homozygous global knockout (Slc1a5−/−) mice was confirmed 
by qRT-PCR and Western blotting analyses (Supplementary Fig. 2c, d). Despite the 
profound impact of Gln deprivation on HSC differentiation in vitro (which might result from 
combined effects of Gln starvation and oxidative stress during the culture), surprisingly, 
Slc1a5−/− mice were born at the Mendelian ratio and had normal lifespans without obvious 
abnormalities. White blood cell (WBC) counts in the peripheral blood (PB) were lower in 
Slc1a5−/− mice than their wild-type (Slc1a5+/+) littermates, but no differences in red blood 
cells or platelets were observed between knockout and control animals (Supplementary Fig. 
3a). Total BM cellularity slightly decreased in Slc1a5−/− mice (Supplementary Fig. 3b). 
Frequencies of myeloid (Mac-1+Gr-1+), T lymphoid (CD3+), and B lymphoid (B220+) cells 
in the PB or BM were similar in Slc1a5−/− and Slc1a5+/+ mice (Supplementary Fig. 3c). 
Although a previous study showed that ASCT2 was required for erythroid specification in 
human CD34+ cells 21, we observed no effects of loss of ASCT2 on erythroid cell 
development in steady state hematopoiesis. Erythroid blasts in four differentiation stages 
developed without noticeable defects in Slc1a5 knockout mice (Supplementary Fig. 3d).
Slc1a5−/− mice had a marginal decrease in the frequencies and absolute numbers of HSCs 
(Lin−Sca-1−c-Kit+CD150+CD48−), LSK (Lin−Sca-1+c-Kit+) and LK (Lin−c-Kit+) cells in 
the BM compared to Slc1a5+/+ control animals (Fig.1a). Frequencies and absolute numbers 
of common lymphoid progenitors (CLPs, Lin−c-Kit lowSca-1lowCD127+), common myeloid 
progenitors (CMPs, Lin−c-Kit+Sca-1−CD16/32medCD34+), granulocyte-monocyte 
progenitors (GMPs, Lin−c-Kit+Sca-1−CD16/32highCD34+), and megakaryocyte-erythroid 
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progenitors (MEPs, Lin−c-Kit+Sca-1−CD16/32med/lowCD34−) were lower in Slc1a5−/− mice 
than those in Slc1a5+/+ mice (Fig. 1b). Consistent with these phenotypic data, functional 
analyses verified that colony forming unit (CFU)-granulocyte-erythroid-macrophage- 
megakaryocyte (CFU-GEMM), CFU-granulocyte-macrophage (CFU-GM), and burst-
forming unit-erythroid (BFU-E) were slightly decreased in the BM in Slc1a5−/− mice (Fig. 
1c). Slc1a5 knockout LSK cells and HSCs cycled faster than Slc1a5+/+ cells (possibly due to 
a compensatory response to the defects in blood cell production), and knockout cells 
displayed reduced quiescence in 6–8 week-old adult mice. Percentages of Slc1a5−/− LSK 
cells and HSCs in the G1 and S/G2/M phases were increased while the percentage of the G0 
phase cells was decreased (Fig. 1d). In addition, apoptosis increased by > 2-fold in LSK 
cells and HSCs in Slc1a5−/− mice compared to that in Slc1a5+/+ mice (Fig. 1e). Consistent 
with the phenotypic HSC data, competitive repopulation assays verified that Slc1a5−/− BM 
cells had reduced repopulation capabilities. Reconstitution of the entire hematopoietic cell 
population (Fig. 1f, g), LSK cells (Fig. 1h), and each lineage (myeloid, T and B lymphoid) 
(Supplementary Fig. 3e) from Slc1a5−/− BM cells was decreased from expected 50% to 
~30%, when competing with the same amount of wild-type BM cells in primary and 
secondary transplants.
We also generated hematopoietic cell conditional knockout mice (Slc1a5fl/flMx1-Cre) by 
crossing Slc1a5fl/+ mice with Mx1-Cre mice, which express DNA recombinase Cre in 
response to polyinosinic-polycytidylic acid (pI-pC) administration 22. Following pI-pC-
induced deletion of Slc1a5 (Supplementary Fig. 4a), similarly mild defects in the 
hematopoietic system were observed in Slc1a5Δ/Δ mice (Supplementary Fig. 4b). In 
addition, acute deletion of Slc1a5 compromised HSC abilities to reconstitute the 
hematopoietic system in primary and secondary transplants in competitive repopulation 
assays (Supplementary Fig. 4c, d). Notably, when challenged with the cell cycle-dependent 
myelotoxic agent 5-fluorouracil (5-FU) (one dose), which kills cycling cells, and spares 
quiescent stem cells, Slc1a5−/− mice displayed markedly delayed recovery of WBC counts, 
compared to Slc1a5+/+ control mice (Fig. 1i). In response to two lower doses of 5-FU, all 
Slc1a5−/− mice died with hematopoietic failure, whereas 75% of Slc1a5+/+ mice survived 
(Fig. 1j). Furthermore, the recovery of WBC counts in sublethally irradiated (5 Gy) 
Slc1a5−/− mice was also significantly delayed. Two weeks after the irradiation, total BM cell 
numbers, LSK cells, and HSCs were much lower in Slc1a5−/− mice than those in Slc1a5+/+ 
control mice (Supplementary Fig. 5a–d). Collectively, these data suggest that ASCT2 is 
important for optimal HSC function in stress hematopoiesis, but not for BM and mature 
blood cell development under steady state conditions.
Role of ASCT2 in cellular metabolism is mediated by Gln and other AAs
ASCT2 is a transporter for neutral AAs and thought as a high affinity Gln transporter 13. To 
determine whether the role of ASCT2 in HSCs was attributable to Gln transport, we 
examined Gln uptake in Slc1a5−/− and Slc1a5+/+ Lin− cells and found that it was decreased 
by ~3-fold but not completely blocked in the knockout cells (Supplementary Fig. 6a). We 
also assessed responses of Slc1a5−/− and Slc1a5+/+ HSCs and LSK cells to low 
concentrations of Gln in in vitro culture. Slc1a5−/− cells were much more sensitive than 
Slc1a5+/+ counterparts to low Gln concentrations-induced apoptosis (Supplementary Fig. 
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6b–d). Interestingly, even in the absence of Gln, Slc1a5−/− LSK cells still showed more 
apoptosis than did Slc1a5+/+ cells (Supplementary Fig. 6d), indicating that other AA 
substrates of ASCT2 may also mediate ASCT2 function.
Gln is an important carbon source and serves as an alternative fuel to support mitochondrial 
oxidative phosphorylation. We next assessed mitochondrial aerobic metabolism in intact, 
viable Lin− cells by real-time measurement of oxygen consumption. In the presence of Gln, 
Slc1a5 knockout cells showed lower basal oxygen consumption rates (OCRs) and maximal 
oxidative capacity compared to control cells (Supplementary Fig. 6e), suggesting decreased 
mitochondrial aerobic metabolism in Slc1a5 knockout cells. In the absence of Gln, the 
difference in mitochondrial maximal reserve capacities between Slc1a5−/− and Slc1a5+/+ 
cells persisted, further supporting that loss of ASCT2 impacted cellular metabolism also by 
decreasing the uptake of other neutral AAs besides Gln. Measurement of extracellular 
proton flux showed that in the presence of Gln, Slc1a5-depleted cells had increased 
extracellular acidification rates (ECARs) (Supplementary Fig. 6f), indicative of enhanced 
glycolysis. Deprivation of Gln compensatorily enhanced glycolysis in Slc1a5+/+ but not 
Slc1a5−/− cells (Supplementary Fig. 6f). Autophagy in Slc1a5−/− cells (Lin−) was possibly 
enhanced as demonstrated by elevated LC3-II levels (Supplementary Fig. 6g). Steady state 
total cellular ATP levels were decreased in Slc1a5−/− cells compared to those in control cells 
(Supplementary Fig. 6h), and AMP-activated kinase (AMPK), an intracellular energetic 
stress sensor, was activated in Slc1a5 knockout cells (Supplementary Fig. 6i). Consistent 
with these data, mTOR, the nutrient-sensor and the mast regulator of protein translation, was 
inhibited in Slc1a5−/− cells as evidenced by decreased phosphorylation of ribosomal protein 
S6 kinase 1 (S6K1) and S6 (Supplementary Fig. 6i).
Deletion of ASCT2 inhibits MLL-AF9-induced leukemia
We next examined the role of ASCT2 in leukemogenesis in vivo. Lin− BM cells isolated 
from Slc1a5−/− and Slc1a5+/+ mice were transduced with AML-associated oncogene MLL-
AF9 followed by inoculation into sublethally irradiated isogenic normal mice. All of the 
recipient mice (MLL-AF9; Slc1a5+/+) inoculated with MLL-AF9-transduced Slc1a5+/+ cells 
died of AML within 45 days. In sharp contrast, survival of the mice (MLL-AF9; Slc1a5−/−) 
inoculated with MLL-AF9-transduced Slc1a5−/− cells was prolonged by approximately 300 
days (Fig. 2a). Proliferation of MLL-AF9-Slc1a5−/− leukemic cells was markedly decreased 
compared to that of MLL-AF9-Slc1a5+/+ leukemic cells in recipient mice (Fig. 2b). 
Leukemic burden, as reflected by WBC counts (Fig. 2c), spleen weights (Fig. 2d), and 
percentages of leukemic cells (GFP+) in the PB, BM and spleen (Fig. 2e), was dramatically 
decreased in MLL-AF9; Slc1a5−/− recipients. Histopathological examination revealed that 
even 140 days after inoculation, AML phenotypes in the BM and spleen were much less 
severe, and infiltration of leukemic cells in the liver and lung was much reduced in MLL-
AF9; Slc1a5−/− recipients compared to MLL-AF9; Slc1a5+/+ recipients at day 35 (Fig. 2f). 
The decreased AML development in MLL-AF9; Slc1a5−/− mice was likely due to enhanced 
leukemic cell death because apoptosis of GFP+ leukemic cells, but not endogenous 
leukocytes (GFP−), was much increased in these animals (Fig. 2g). MLL-AF9; Slc1a5−/− 
leukemic cells also showed increased apoptosis in culture compared to MLL-AF9; Slc1a5+/+ 
leukemic cells (Fig. 2h), verifying the cell autonomous effects of ASCT2 deletion.
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To exclude a potential impact of ASCT2 deficiency on leukemic cell engraftment in the 
above experiments, and to further determine whether ASCT2 is important for maintenance 
of established leukemia, we utilized Slc1a5 conditional knockout mice and examined the 
effect of acute deletion of Slc1a5 on established AML. BM Lin− cells isolated from 
Slc1a5fl/flMx1-Cre and Slc1a5+/+Mx1-Cre mice (without pI-pC administration) were 
transduced with MLL-AF9 followed by inoculation into sublethally irradiated isogenic mice. 
Fourteen days later when AML was developed (GFP+ leukemic cells in the PB were >10%), 
recipient mice were treated with pI-pC (to delete Slc1a5 from MLL-AF9-transduced 
Slc1a5fl/flMx1-Cre cells). All of the recipient mice (MLL-AF9; Slc1a5+/+) inoculated with 
MLL-AF9-Slc1a5+/+Mx1-Cre leukemic cells died within ~40 days. In contrast, deletion of 
ASCT2 from leukemic cells extended survival of the recipient mice (MLL-AF9; Slc1a5Δ/Δ) 
inoculated with MLL-AF9-Slc1a5fl/flMx1-Cre leukemic cells by approximately 150 days 
(Fig. 3a). Slc1a5 deletion effectively suppressed leukemic cell proliferation in vivo (Fig. 3b). 
Leukemic burden reflected by WBC counts (Fig. 3c), spleen weights (Fig. 3d), and 
percentages of leukemic cells (GFP+) in the PB, BM and spleen (Fig. 3e) was substantially 
decreased. Even at 140 days after leukemic cell inoculation, leukemic phenotypes in the BM 
and spleen were much less severe, and infiltration of leukemic cells in the liver and lung was 
much milder in MLL-AF9; Slc1a5Δ/Δ recipients than those in MLL-AF9; Slc1a5+/+ 
recipients at day 35 (Fig. 3f). Apoptosis of GFP+ leukemic cells, but not endogenous host 
leukocytes (GFP−), was doubled in MLL-AF9; Slc1a5Δ/Δ mice compared to that in MLL-
AF9; Slc1a5+/+ mice (Fig. 3g).
Deletion of ASCT2 suppresses Pten loss-evoked blood malignancies
We next utilized a mouse genetics approach to further assess the role of ASCT2 in the 
development and progression of hematological malignancies. Ptenfl/flMx1-Cre; Slc1a5+/+ 
and Ptenfl/flMx1-Cre; Slc1a5−/− mice were generated with Pten conditional and Slc1a5 
global knockout mice. Even without pI-pC administration, Pten was partially deleted from 
these mice due to the spontaneous activation of the Mx1 promoter and Cre expression by 
endogenous basal IFN-α/β 23. Interestingly, Pten deletion efficiency in Ptenfl/flMx1-Cre; 
Slc1a5−/− mice was substantially lower than that in Ptenfl/flMx1-Cre; Slc1a5+/+ mice 
(Supplementary Fig. 7a), indicating a growth disadvantage of Pten/Slc1a5 double knockout 
cells relative to Pten single knockout cells. Loss of Pten resulted in myeloproliferative 
neoplasm (MPN) in Ptenfl/flMx1-Cre; Slc1a5+/+ mice, consistent with previous studies 24,25. 
These mice manifested elevated WBCs and increased myeloid cells (Mac-1+Gr-1+) in the 
PB when they were 6–8 weeks old. However, no Ptenfl/flMx1-Cre; Slc1a5−/− mice showed 
MPN at this time point (Supplementary Fig. 7b, c).
Ptenfl/flMx1-Cre; Slc1a5−/− (PtenΔ/Δ; Slc1a5−/−) and Ptenfl/flMx1-Cre; Slc1a5+/+ (PtenΔ/Δ; 
Slc1a5+/+) mice were then administered pI-pC to further delete Pten. PtenΔ/Δ; Slc1a5+/+ 
mice developed severe MPN, and two of the nine mice progressed into AML. They all died 
within 60 days of pI-pC administration. In sharp contrast, survival of PtenΔ/Δ; Slc1a5−/− 
mice was prolonged by >250 days (Fig. 4a). Although PtenΔ/Δ; Slc1a5−/− mice subsequently 
developed MPN and died within 400 days of pI-pC administration, no acute leukemia 
progression was detected. WBC counts (Fig. 4b), splenomegaly (Fig. 4c), and myeloid cells 
in the PB, spleen and BM were greatly decreased in PtenΔ/Δ; Slc1a5−/− mice as compared to 
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PtenΔ/Δ; Slc1a5+/+ control mice 45 days after pI-pC administration (Fig. 4d). 
Histopathological examination verified that leukemic phenotypes in the BM and spleen were 
much attenuated, and infiltration of neoplastic cells in the liver and lung was barely 
detectable in PtenΔ/Δ; Slc1a5−/− mice at this time point (Fig. 4e). These data suggest that 
ASCT2 is essential for the initiation of hematological malignancies induced by loss of Pten.
To further determine the effect of ASCT2 deletion on maintenance of established 
hematological malignancies induced by Pten deletion, we generated Ptenfl/flMx1-Cre; 
Slc1a5+/+ and Ptenfl/flMx1-Cre; Slc1a5fl/fl mice with Pten and Slc1a5 conditional mice. As 
described above, due to the spontaneous activation of the Mx1 promoter and Pten deletion 
(Supplementary Fig. 7d), Ptenfl/flMx1-Cre; Slc1a5+/+ control mice developed MPN when 
they were 6–8 weeks old. Ptenfl/flMx1-Cre; Slc1a5fl/fl mice also displayed MPN phenotypes 
(Supplementary Fig. 7e–g). Interestingly, although Pten was similarly deleted (~75%) in 
both types of mice, Slc1a5 was only deleted from ~ 40% of hematopoietic cells in 
Ptenfl/flMx1-Cre; Slc1a5fl/fl mice (Supplementary Fig. 7d), further supporting the important 
role of ASCT2 for the growth of Pten-deleted malignant cells.
Ptenfl/flMx1-Cre; Slc1a5+/+ (PtenΔ/Δ; Slc1a5+/+) and Ptenfl/flMx1-Cre; Slc1a5fl/fl (PtenΔ/Δ; 
Slc1a5Δ/Δ) diseased mice were then administered pI-pC to delete Slc1a5 and further delete 
Pten. Three of the 12 PtenΔ/Δ; Slc1a5+/+ mice progressed into AML, whereas acute leukemia 
progression was completely blocked in PtenΔ/Δ; Slc1a5Δ/Δ mice. All PtenΔ/Δ; Slc1a5+/+ mice 
died with hematological malignancies within 50 days of pI-pC administration. In contrast, 
the survival of double knockout (PtenΔ/Δ; Slc1a5Δ/Δ) mice was significantly extended 
(Supplementary Fig. 8a). WBCs in the PB, splenomegaly, and malignant cell infiltration in 
non-hematopoietic tissues were much attenuated in PtenΔ/Δ; Slc1a5Δ/Δ mice as compared to 
PtenΔ/Δ; Slc1a5+/+ control littermates (Supplementary Fig. 8b–e). These data suggest that 
ASCT2 also plays an important role in the maintenance of hematological malignancies 
driven by Pten deletion.
To verify that the impact of ASCT2 deletion on MPN development and acute leukemic 
progression is a cell-autonomous effect, we transplanted BM cells isolated from 
Ptenfl/flMx1-Cre; Slc1a5+/+ and Ptenfl/flMx1-Cre; Slc1a5fl/fl mice (without pI-pC 
administration) into lethally irradiated isogenic mice. Five weeks after transplantation, 
recipient mice were treated with pI-pC to delete Pten (PtenΔ/Δ; Slc1a5+/+) or both Pten and 
Slc1a5 (PtenΔ/Δ; Slc1a5Δ/Δ) from donor cells. All of PtenΔ/Δ; Slc1a5+/+ recipients developed 
MPN and progressed into acute leukemias (AML and T cell acute lymphocytic leukemia). In 
contrast, only 40% of PtenΔ/Δ; Slc1a5Δ/Δ recipients showed acute leukemia progression (the 
other 60% of the mice retained in MPN), and splenomegaly was much attenuated in these 
mice (Supplementary Fig. 8f, g), reaffirming a critical cell intrinsic role of ASCT2 in the 
development and progression of hematological malignancies.
Loss of ASCT2 causes metabolic stress and apoptosis in leukemic cells
The mechanisms underlying the critical role of ASCT2 in leukemic cells were investigated. 
Compared to PtenΔ/Δ; Slc1a5+/+ Lin− cells, PtenΔ/Δ; Slc1a5−/− counterparts showed 
decreased mitochondrial aerobic metabolism as evidenced by reduced basal and maximal 
reserve OCRs (Fig. 5a, c). Interestingly, PtenΔ/Δ; Slc1a5−/− cells also displayed lower 
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ECARs than PtenΔ/Δ~; Slc1a5+/+ cells (Fig. 5b, c). Reduction in both OCRs and ECARs in 
PtenΔ/Δ; Slc1a5−/− cells might be associated with increased apoptosis in these cells and 
indicates that PtenΔ/Δ; Slc1a5−/− cells became metabolically less active compared to highly 
energetic PtenΔ/Δ; Slc1a5+/+ leukemic cells. Ablation of ASCT2 in PtenΔ/Δ; Slc1a5−/− cells 
decreased ATP levels (Fig. 5d), although overall cellular reactive oxygen species (ROS) 
levels were not significantly changed (Fig. 5e), and autophagy was possibly enhanced in 
these cells as demonstrated by elevated LC3-II levels (Fig. 5f). Loss of ASCT2 caused 
pronounced cell cycle arrest in the G0 phase, and greatly increased apoptosis was detected in 
PtenΔ/Δ; Slc1a5−/− cells (Fig. 5g, h).
ASCT2 deletion generates a global effect on leukemia cell metabolism
We next sought to determine the molecular mechanisms by which ASCT2 deletion impacts 
leukemic cell metabolism. ASCT2 is known as a high affinity transporter for Gln 13, which 
participates in mitochondrial metabolism, synthesis of the cellular primary antioxidant 
glutathione, among other activities 6,26,27. Gln uptake in ASCT2-depleted PtenΔ/Δ; Slc1a5−/− 
leukemic cells (Lin−) was decreased by ~ 20-fold (Fig. 6a). Interestingly, intermediate 
metabolites of the TCA cycle, α-ketoglutarate (α-KG) and acetyl-CoA, were not 
significantly changed in PtenΔ/Δ; Slc1a5−/− cells (Fig. 6b, c), indicating that enhanced cell 
death in ASCT2-deleted leukemic cells might not result from disruption of TCA cycle 
anaplerosis. The reduced (GSH) and oxidized (GSSG) glutathione ratio was decreased in 
these cells (Fig. 6d). Gln metabolism has an intricate interplay with glucose metabolism 
6,26,27; interestingly, despite the drastically decreased Gln uptake, glucose uptake in PtenΔ/Δ; 
Slc1a5−/− cells was reduced compared to that in PtenΔ/Δ; Slc1a5+/+ control cells (Fig. 6e), 
and pyruvate, a key metabolite of glucose, was increased in PtenΔ/Δ; Slc1a5−/− cells (Fig. 
6f).
Mass spectrometry-based comprehensive metabolomic profiling revealed that deletion of 
ASCT2 in Pten deleted cells resulted in a global effect on cellular metabolism. Several 
metabolic pathways were severely impacted (Fig. 6g, Supplementary Fig. 9a, Table 1). 
Glycolytic and pentose phosphate pathways were attenuated in PtenΔ/Δ; Slc1a5−/− cells, as 
demonstrated by a marked decrease in glucose-6-phosphate (G6P), Ribulose-5-phosphate 
(Ru5P), and NADPH levels (Supplementary Fig. 9b). Surprisingly, Gln levels were not 
significantly changed in PtenΔ/Δ; Slc1a5−/− cells (possibly because it could be partially 
synthesized in cells) (Supplementary Fig. 9a, b). However, loss of ASCT2 decreased 
branched-chain AAs in these cells (Supplementary Fig. 9c). In addition, levels of Cys and 
Thr were greatly decreased in ASCT2-depleted leukemic cells (Supplementary Fig. 9d). 
Despite these changes, purine and pyrimidine levels only marginally decreased 
(Supplementary Fig. 9e). Consistent with these massive metabolic changes, mTOR (both 
mTORC1 and mTORC2) signaling was inhibited as demonstrated by substantially decreased 
p-mTOR, p-S6K1, p-S6, and p-Akt (S473) in PtenΔ/Δ; Slc1a5−/− cells (Fig. 6h). Cell survival 
and growth signaling, as reflected by p-Akt (T308) and p-Erk, was also decreased in ASCT2-
deleted leukemic cells. Immunohistochemical staining displayed greatly decreased p-S6K1 
in the BM cells of PtenΔ/Δ; Slc1a5−/− mice (Fig. 6i), confirming low mTORC1 activity in 
Slc1a5 knockout leukemic cells in vivo.
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Loss of ASCT2 inhibits leucine influx and mTOR signaling
To further define the mechanism underlying the enhanced apoptosis in ASCT2 deleted 
leukemic cells, we performed rescue experiments in PtenΔ/Δ; Slc1a5−/− cells. Treatments 
with cell permeable nucleosides, which can be phosphorylated in cells to produce 
nucleotides, the anti-oxidant N-acetyl-cysteine (NAC), and the cell-permeable α-KG analog 
dimethyl-α-KG, which should fulfill many of the bioenergetic roles of Gln, failed to rescue 
PtenΔ/Δ; Slc1a5−/− cells (Fig. 7a–c). Given that Gln uptake was dramatically decreased and 
that mTOR signaling was diminished in PtenΔ/Δ; Slc1a5−/− cells, we reasoned that leucine 
(Leu) influx, which relies upon Gln efflux for activating mTOR 28, might be reduced in 
these cells. Indeed, Leu uptake decreased by half in PtenΔ/Δ; Slc1a5−/− cells compared to 
PtenΔ/Δ; Slc1a5+/+ cells (Fig. 7d). Treatment with cell-permeable Leu analog (L-Leucyl-L-
Leucine methyl ester; LLME) 29, which does not require cell transporters to enter cells, 
reversed the increased apoptosis in PtenΔ/Δ; Slc1a5−/− cells (Fig. 7e). LLME treatment 
mitigated cell cycle arrest and senescence in these cells (Fig. 7f, g). Treatment with the 
mTOR activator MHY1485 also effectively improved survival in PtenΔ/Δ; Slc1a5−/− cells 
(Fig. 7h). Importantly, LLME largely corrected mTOR signaling in PtenΔ/Δ; Slc1a5−/− cells 
(Fig. 7i), suggesting that the enhanced leukemic cell death induced by ASCT2 deletion was 
attributable to subsequently decreased Leu uptake and diminished mTOR activity.
Furthermore, to verify the role of decreased Leu uptake in the increased apoptosis of Slc1a5 
deleted leukemic cells in vivo, we treated MLL-AF9; Slc1a5−/− and PtenΔ/Δ; Slc1a5−/− 
leukemic mice with LLME, which showed substantially prolonged survival compared to 
MLL-AF9; Slc1a5+/+ and PtenΔ/Δ; Slc1a5+/+ leukemic mice (Fig. 2a, 4a). LLME treatment 
markedly shortened their survival due to increased leukemic burden and progression, 
whereas MLL-AF9; Slc1a5+/+ mice were not affected by LLME treatment (Fig. 7j–o). These 
in vitro and in vivo rescue data collectively suggest that the enhanced leukemic cell death 
induced by ASCT2 loss was mainly attributed to subsequently decreased Leu influx and 
inhibition of mTOR.
Likewise, Leu uptake decreased in Slc1a5-deleted normal cells (Lin−) compared to 
undeleted counterparts (Supplementary Fig. 10a). Slc1a5−/− HSCs and LSK cells cultured in 
a low concentration of Gln were partially rescued by treatment with LLME or MHY1485, 
and mTOR signaling was largely corrected by LLME and MHY1485 (Supplementary Fig. 
10b–e). Interestingly, Slc1a5 deleted normal cells also showed partial rescue responses to 
dimethyl-α-KG (Supplementary Fig. 10b–e), in contrast to Slc1a5 deleted leukemic cells 
(Fig. 7c). Together, these data indicate that both reduced mitochondrial oxidative 
phosphorylation and diminished mTOR signaling caused by ASCT2 deficiency contributed 
to the increased apoptosis in Slc1a5-deleted normal cells, whereas in Slc1a5 deleted 
leukemic cells, defective mTOR signaling, but not mitochondrial metabolic defects, was 
responsible for the increased cell death.
Slc1a5-deleted leukemic cells (PtenΔ/Δ; Slc1a5−/−) and Slc1a5-undeleted control leukemic 
cells (PtenΔ/Δ; Slc1a5+/+) showed similar sensitivity to further Gln deprivation 
(Supplementary Fig. 10f, g), although PtenΔ/Δ; Slc1a5−/− cells exhibited elevated apoptosis 
in the presence of saturated Gln (2 mM). Treatments with cell permeable analogs of Gln, 
Leu, Cys, Val, or Arg, but not Lys, partially reversed the increased apoptosis in PtenΔ/Δ; 
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Slc1a5−/− cells. Notably, among the AAs tested, LLME showed the best rescue effect 
(Supplementary Fig. 10h). These data suggest that the enhanced cell death caused by 
ASCT2 depletion in leukemic cells was mainly caused by greatly decreased Gln uptake and 
subsequent defective Leu influx, yet, reduced transport of other substrate AAs also 
contributed to the decreased survival of Slc1a5 knockout leukemic cells. In addition, to 
determine whether LLME acted as a bona fide Leu donor, we deprived PtenΔ/Δ; Slc1a5+/+ 
leukemic cells of Leu in the presence or absence of LLME. Leu deprivation induced 
apoptosis in PtenΔ/Δ; Slc1a5+/+ cells, phenocopying PtenΔ/Δ; Slc1a5−/− cells. LLME 
treatment reversed apoptosis in PtenΔ/Δ; Slc1a5+/+ cells deprived of Leu, whereas it did not 
affect the survival of un-starved PtenΔ/Δ; Slc1a5+/+ cells (Supplementary Fig. 10i).
Inhibition of ASCT2 suppresses human AML in xenograft models
Given the significant difference in responses to Slc1a5 (ASCT2) deletion between normal 
hematopoietic cells (except stress conditions) and malignant cells, and the remarkable 
effects of ASCT2 deletion on leukemia initiation and maintenance in mouse leukemias, we 
tested for the potential therapeutic effect of pharmacological blockade of ASCT2 in human 
AML. Treatment of patient primary AML cells with L-c-glutamyl-p-nitroanilide (GPNA), 
an inhibitor of ASCT2 30, decreased cell survival (Fig. 8a) and increased apoptosis in vitro 
(Fig. 8b). However, no significant effects on cell survival were observed in normal BM cells 
(Fig. 8a, b). Functional colony assays verified that GPNA markedly decreased the abilities of 
AML cells, but not normal BM progenitors, to form colonies (Supplementary Fig. 11a), 
indicative of a potential therapeutic index of ASCT2 inhibition.
We next set up xenograft models of human AML in NOD/SCID-IL2RG (NSG) mice. When 
hCD45+ AML cells became detectable, xenografted mice were treated with GPNA or 
vehicle for 4 weeks. GPNA treatment effectively suppressed leukemia progression. 
Splenomegaly and hepatomegaly were attenuated (Fig. 8c, d). WBCs in the PB of GPNA-
treated leukemic mice were decreased (Supplementary Fig. 11b). Furthermore, CD34+ 
patient AML cells drastically decreased in the PB and BM following the treatment with 
GPNA (Fig. 8e, f). Compared to vehicle-treated mice, GPNA-treated leukemic mice showed 
greatly increased apoptosis in human leukemic cells in both the PB and BM (Fig. 8e, f). 
Pathological examination verified that leukemic phenotypes in the BM and spleen were 
attenuated, and infiltration of leukemic cells into non-hematopoietic organs was much 
reduced in GPNA-treated mice (Supplementary Fig. 11c). These preclinical data validate the 
critical role of ASCT2 in human leukemia development/progression. This notion is further 
supported by the correlation of SLC1A5 amplification or high expression with poor 
prognosis in human AML patients (Supplementary Fig. 11d), and that mutations in four 
AML-associated genes (TP53, XIAP, PHF6, and GRIK4) have a tendency to significantly 
co-occur with SLC1A5 amplification (Supplementary Fig. 11e).
DISCUSSION
Although many AAs have been shown to be important for cancer cell metabolism and 
growth, little progress has been made in finding therapeutic targets (except for L-
asparaginase) in AA metabolic pathways that can be harnessed to kill cancer cells but spare 
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normal cells. In this report, we demonstrate in in vivo settings that normal and malignant 
hematopoietic cells had remarkably differential responses to blockade of ASCT2-mediated 
AA metabolism. Slc1a5 (ASCT2) knockout mice had normal lifespans without noticeable 
abnormalities. This AA transporter was not critically important for mature blood cell 
production in steady state hematopoiesis although it was required for optimal HSC 
regenerative capabilities under stress conditions. ASCT2 deletion showed only mild to 
moderate effects on blood cell development, consistent with recent findings that ASCT2 was 
dispensable for homeostatic T cell development although it was important for T cell 
activation 31, and that no abnormalities were found in B cell development and function in the 
absence of ASCT2 32. In contrast, ASCT2 was much more important for leukemia 
development and progression. Constitutive or induced deletion of ASCT2 greatly decreased 
initiation and maintenance of hematological malignancies driven by MLL-AF9 or Pten 
deficiency. Survival of ASCT2-deleted leukemic mice was prolonged by 200–300 days. 
Furthermore, pharmacological inhibition of ASCT2 produced a significant therapeutic effect 
in xenograft models of human AML, while the impact on normal blood cell formation was 
minimal.
ASCT2 appears to play a pleotropic role in cell metabolism; enhanced cell death in leukemic 
cells induced by ASCT2 deletion was likely attributed to multiple metabolic defects. 
Although ASCT2 is known as a high affinity Gln transporter 13, and Gln uptake was indeed 
drastically decreased in Slc1a5 knockout leukemic cells, deletion of ASCT2 produced a 
pronounced global effect on cell metabolism, which cannot be fully explained by its function 
in transporting Gln. In fact, Gln and glutamate (Glu) levels were only slightly but not 
significantly reduced in ASCT2-deleted leukemic cells (possibly because Gln could also be 
transported through Slc38a5, Slc38a1 or Slc38a2, and be partially synthesized in cells). 
Other AA substrates beyond Gln might also mediate the function of ASCT2. Levels of Cys, 
Val, Ile, Thr, etc. were significantly decreased in Slc1a5 knockout leukemic cells. These 
AAs are critical for maintenance of intracellular redox homeostasis and robust biosynthesis 
in cancer cells 7,33,34. Conceivably, reduction in the transport of these AAs also contributed 
to the enhanced cell death in ASCT2-deleted leukemic cells. This notion is supported by the 
partial rescue effects of cell permeable analogs of Cys and Val on the survival of Slc1a5-
deleted leukemic cells. Moreover, many other metabolic pathways, such as glycolytic and 
pentose phosphate pathways, and the methylation cycle were diminished in ASCT2-deleted 
leukemic cells. These broad metabolic changes might account for the profound impact of 
ASCT2 deletion/inhibition on leukemic cells and the more efficacious effects of targeting 
ASCT2 over a single enzyme involved in the Gln metabolic pathway in malignant cells.
In addition, functional coupling of ASCT2 with other AA transporter(s) is critical for 
leukemic cell metabolism. The influx of Leu and other AAs requires simultaneous efflux of 
Gln and its derivatives (e.g. Glu) through LAT1 (Slc7a5) 28,35 and other bidirectional 
transporter(s), respectively, although in some cell lines Leu import does not rely upon 
ASCT2 36. Although steady state levels of Gln in ASCT2-deleted leukemic cells were 
slightly reduced, Gln uptake was decreased by ~20-fold in these cells, which could lead to 
reduced Gln efflux rates and thus Leu influx. Decreased Leu uptake in turn resulted in 
diminished mTOR signaling in ASCT2-deleted leukemic cells since a constant intracellular 
pool of Leu is required for activation of mTOR complex 1 (mTORC1) 28,35. Indeed, 
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treatment with cell permeable Leu analog (LLME) not only largely restored mTOR 
signaling but also rescued survival in ASCT2-deleted cells in vitro and in vivo. Therefore, it 
is likely that reduced uptake of Gln and other neutral AAs combined with the functional 
uncoupling of ASCT2 and LAT1 and possibly other bidirectional transporters collectively 
led to the pleotropic metabolic effects of ASCT2 deletion/inhibition in leukemic cells.
Another interesting finding in this report is that normal hematopoietic cells and leukemic 
cells had substantially differential reliance on ASCT2. The effects of ASCT2 deletion on 
both mitochondrial oxidative phosphorylation and mTOR activation were associated with 
the decreased survival in normal hematopoietic stem/progenitor cells as cell-permeable α-
KG analog and the mTOR activator rescued Slc1a5 knockout cells. However, mitochondrial 
metabolic defects caused by ASCT2 deletion did not contribute significantly to the enhanced 
apoptosis in Slc1a5 knockout malignant cells, because α-KG failed to rescue Slc1a5-deleted 
leukemic cells, possibly due to unique rewired/reprogramed metabolic processes in 
malignant cells. Rather, diminished mTOR signing was likely responsible for the increased 
apoptosis in Slc1a5-deleted leukemic cells given that LLME (and also the mTOR activator 
MHY1485) effectively restored mTOR signaling and also rescued survival in these cells. 
Transformed cells were much more sensitive to ASCT2 deletion than steady state normal 
stem/progenitor cells. This might be partly due to the rapid proliferation and robust 
biosynthesis and/or reprogramed cellular metabolism in tumor cells. However, detailed 
mechanisms underlying the differential responses to ASCT2 deletion/inhibition between 
normal and malignant hematopoietic cells remain to be determined.
Last, our study suggests that ASCT2 holds great promise as an effective molecular target for 
the treatment of leukemia. The ASCT2 inhibitor GPNA showed a significant therapeutic 
effect in xenograft models of human AML in this study; however, the potency of GPNA is 
low and it is not specific for ASCT2. It also inhibits sodium-independent carriers 37,38. More 
recently, a new selective and potent ASCT2 antagonist (V-9302) has been developed 18. 
V-9302 inhibited the uptake of Gln and other neutral AAs with much improved potency. 
This drug produced a marked therapeutic effect in nude mice xenografted with colon cancer 
cell lines 18. Nevertheless, it is important to note that although our overall findings strongly 
suggest ASCT2 as a therapeutic target for leukemia treatment, cautions should be exercised 
in clinical trials when considering combined treatments with ASCT2 inhibition and DNA 
damaging chemotherapy, which imposes tremendous stress on HSCs. Given that ASCT2 is 
required for optimal HSC regenerative capabilities under stress conditions, combined 
treatments might cause severe adverse effects on normal hematopoiesis in patients.
METHODS
Mice and patient samples.
Slc1a5fl/+ mice (in the C57BL/6J genetic background) were generated by a conventional 
gene-targeting strategy, in which exons 2–4 were flanked by two loxp sites, through 
homologous recombination. CMV-Cre (Stock #006054), Mx1-Cre (Stock #003556), and 
Ptenfl/+ (Stock #006440) mice in the C57BL/6J background were purchased from the 
Jackson Laboratory. Slc1a5fl/+ mice were crossed with CMV-Cre transgenic mice to delete 
Slc1a5 from the germline to generate global heterozygous knockout (Slc1a5+/−) mice. 
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Slc1a5fl/+ mice were also crossed with Mx1-Cre mice to generate inducible hematopoietic 
cell knockout (Slc1a5fl/flMx1-Cre) mice. Mice of the same age (specified in figure legends), 
sex, and genotype (often from the same litters, but not always) were mixed and then 
randomly grouped for subsequent analyses (investigators were not blinded). Mice were kept 
under specific-pathogen-free conditions at Emory University Division of Animal Resources. 
All animal procedures complied with the NIH Guidelines for the Care and Use of 
Laboratory Animals. Experiments involving leukemia induction in mice were approved by 
the Institutional Animal Care and Use Committee (IACUC). Mice were monitored daily for 
the sign of discomfort and pain by our laboratory personnel as well as the staff at the 
Division of Animal Resources Facility. In addition to monitoring the pathological status of 
the mice, we followed IACUC guidelines for endpoints. Any animals showing signs of 
discomfort, pain or distress listed in IACUC guidelines and recommended for euthanization 
by the animal resources facility staff were sacrificed. De-identified BM biopsies from AML 
patients without any patient information were obtained from Emory University Hospital. 
The experiments involving human subjects were reviewed and approved (Exemption IV) by 
the Institutional Review Board of Emory University.
Flow cytometry analysis.
For isolation of Lin− cells, BM cells were lineage-depleted using a lineage depletion kit 
(Miltenyi Biotec Inc.). The pool size, cell cycle status, and apoptosis of HSCs and LSK cells 
were analyzed by multiparameter fluorescent activated cell sorting (FACS) analyses, as 
previously described 19,39. In brief, BM cells freshly harvested from femurs and tibias were 
stained with antibodies labeled with various fluorochromes (eBiosciences, Inc., and BD 
Biosciences). For cell cycle analyses, freshly collected BM cells were stained for HSC 
markers as above, fixed and permeabilized using a Cytofix/Cytoperm kit (BD Biosciences), 
stained with Ki-67 antibody, and further incubated with Hoechest 33342 (20 μg/ mL). For 
apoptosis analyses, fresh BM cells were stained for HSCs, and then incubated with Annexin 
V and 7-amino-actinomycin D (BD Biosciences). To measure cellular reactive oxygen 
species (ROS) levels, cells were incubated in PBS containing 2’−7’-dichlorofluorescein 
diacetate (DCF-DA) (5 μM) at 37 °C for 15 min. Cells were then washed with PBS. ROS 
(H2O2) levels were quantified by FACS analyses. To measure glucose uptake, cells were 
incubated with 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-
NBDG) (200 μM) at 37 °C for 30 min. Cells were washed with PBS and then analyzed by 
FACS. To measure senescent cells, cells were incubated with 5-
Dodecanoylaminofluorescein Di-β-D-Galactopyranoside (C12-FDG) (33 μM) for 1 hour, 
followed by FACS analyses. Data were collected on BD LSR II Flow Cytometer (BD 
Biosciences) and analyzed with FlowJo (Treestar). Cell gating strategies used in FACS 
analyses and cell sorting are shown in Supplementary Figure S12.
Colony-forming unit assay.
Freshly harvested mouse BM cells (2×104 cells/ml) were plated in triplicate in 35-mm 
dishes in 0.9% methylcellulose IMDM medium containing 15% fetal bovine serum (FBS), 
Gln (10−4 M), β-mercaptoethanol (3.3×10−5 M), SCF (50 ng/ml), IL-3 (20 ng/ml), IL-6 (20 
ng/ml), and EPO (3 Units/ml). After 10 days of incubation at 37 °C in 5% CO2, 
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hematopoietic colonies (CFU-GEMM, CFU-GM, and BFU-E) were counted under an 
inverted microscope.
For human marrow cell CFU assays, marrow biopsies from AML patients or normal 
individuals (1×105 cells/ml) were plated in triplicates in 35-mm dishes in 0.9% 
methylcellulose IMDM medium containing 15% FBS, hSCF (50 ng/ml), hIL-3 (10 ng/ml), 
hIL-6 (10 ng/ml), hGM-CSF (25 ng/ml), and EPO (3 Units/ml). GPNA (1 mM, Sigma-
Aldrich) or vehicle was added into the culture medium. Cells were incubated at 37 °C in 5% 
CO2 for 10 days. Colonies were scored with an inverted microscope.
Competitive repopulation assay.
Total test BM cells (2×106) freshly harvested from Slc1a5−/− and Slc1a5+/+ mice (CD45.2+) 
were transplanted with the same number of BM cells (competitor cells) isolated from BoyJ 
mice (CD45.1+) into lethally irradiated (1,100 rad) BoyJ recipients through tail vein 
injection. Test cell reconstitution (CD45.2+ cells) in the whole cell population was 
determined at 4, 8, 12, and 16 weeks after transplantation by FACS analyses of peripheral 
blood (PB) and BM cells as we previously described 11,12. BM cells harvested from 
recipients 16 weeks after primary transplantation were transplanted (1×106 cells /mouse) 
into lethally irradiated secondary BoyJ recipients. Test cell reconstitution in the PB and BM 
cells was determined by FACS 4, 8, 12, and 16 weeks after secondary transplantation as 
above.
Retroviral BM cell transduction.
For virus packaging, retroviral constructs MSCV-MLL-AF9-IRES-GFP were co-transfected 
with pEQ-Pam3 (-E) and pSRαG packaging vectors into HEK293T cells using Calcium-
phosphate-mediated transfection. Virus-containing supernatant was collected 48–72 hours 
post-transfection and used for infection. In brief, Lin− cells isolated from the BM were 
incubated in IMDM supplemented with SCF (50 ng/ml), TPO (50 ng/ml), IL-3 (10 ng/ml), 
and IL-6 (10 ng/ml) (all from Peprotech) for 24 hours. Cells were then spin-infected with 
retroviral supernatant supplemented with polybrene (8 ng/ml) at 490 g for 45 min at 20°C. 
Infected cells were transplanted into sublethally irradiated (700 rad) BoyJ mice (5×105/
mouse) by tail vein injection for in vivo expansion of leukemic cells for six weeks. GFP+ 
cells were sorted from the BM of these mice and then transplanted into sublethally irradiated 
new batches of BoyJ mice (1×105 cells /mouse).
Diagnosis of MPN and AML in mice.
Diagnosis of genetically modified mice or leukemic cell transplants was made as described 
in previous reports from our laboratory and others 24,25,39,40. Specific criterion for MPN, 
AML or T-ALL are listed in Supplementary Table 2.
Measurement of oxygen consumption.
Measurement of intact cellular respiration was performed using XFp Metabolic Flux 
Analyzer (Seahorse Bioscience). In brief, Lin− cells were seeded onto a Cell-Tak precoated 
XFp cell culture miniplates and incubated in XF Base medium with 25 mM glucose at 37°C 
for 1 hour. Respiration was analyzed in XF Base Medium (containing 25 mM glucose) with 
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or without 10 mM Gln, and in the presence of mitochondrial inhibitor oligomycin (350 nM), 
mitochondrial uncoupling compound arbonylcyanide-4-trifluorometh-oxyphenylhydrazone 
(FCCP) (5 μM), and respiratory chain inhibitor rotenone (1 μM). All measurements were 
performed following manufacturer’s instructions and protocols. Oxygen consumption rates 
(OCRs; pmol/min) and extracellular acidification rates (ECARs; mpH/min) were 
determined.
Intracellular metabolite measurements.
The intracellular levels of pyruvate, α-KG, and acetyl-CoA were determined by using 
commercial kits (Biovision). In brief, 2×106 cells were homogenized in PBS. The 
supernatant was collected, and the proteins were removed by using 10 KD Amicon Ultra 
Centrifugal Filters (Millipore). The flow-through containing the metabolites was used for the 
measurement of pyruvate, α-KG, and acetyl-CoA, following the manufacturer’s instructions. 
Intracellular GSH/GSSG ratio was determined using GSH/GSSG-Glo™ (Promega), 
following the manufacturer’s instructions. Total cellular ATP levels in live cells were 
assessed using an ATP assay kit (Sigma Aldrich).
Measurement of 13C labeled Gln and Leu uptake.
Cells were starved in Gln-free or Leu-free RPMI medium for 4 hours. 13C5-Gln (Toronto 
Research Chemicals) (10 mM) or 13C1-Leu (Cambridge Isotope Laboratories) (10 mM) was 
then added to the medium. After 10 min of incubation, cells were washed twice with cold 
PBS and 5 ml MeOH, snap-frozen three times, and centrifuged (3,000 g, 30 min) to remove 
cell debris. After sample normalization based on total protein levels, absolute levels of 
amino acids in the supernatants were quantified using liquid chromatography/tandem mass 
spectrometry (LC/MS/MS).
Metabolomic analysis.
Six to eight-week-old PtenΔ/Δ; Slc1a5+/+ and PtenΔ/Δ; Slc1a5−/− mice were administrated 
with 3 doses of pI-pC (1.0 μg/g body weight) every other day over 5 days to delete Pten 
gene. Ten days later, Lin− cells were freshly isolated from the BM for metabolome analyses. 
In brief, cells were washed in 5% mannitol and then plunged into methanol that contained 
internal standard solution (provided by Human Metabolome Technologies America) for 
cations and anions. The supernatants were extracted and prepared for analyses according to 
the protocol provided by Human Metabolome Technologies America. The extracted samples 
were further prepared for metabolome analyses using an Agilent Capillary Electrophoresis 
Time-of-Flight Mass Spectrometry (CE-TOFMS) system in Human Metabolome 
Technologies America.
Statistics and reproducibility.
Unless otherwise noted, data were presented as mean ± SD of biological replicates 
(independent animals/independent experiments) (the n numbers were specified in each 
figure legend). Unpaired two-tailed Student’s t-test was used for statistical comparison of 
two groups. For Kaplan-Meier survival analysis, the Log-rank (Mantel-Cox) test was used to 
determine statistical significance. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 1. Deletion of ASCT2 moderately and severely decreases blood cell development under 
steady state and stress conditions, respectively.
(a-e) BM cells harvested from six to eight-week-old Slc1a5+/+ and Slc1a5−/− mice were 
assayed by FACS analyses for the frequencies and absolute numbers of HSCs, LSK and LK 
cells (n=5 mice/genotype) (a), and the frequencies and numbers of CLPs, CMPs, GMPs, and 
MEPs (n=7 mice/genotype) (b). BM cells were assessed by CFU assays for the indicated 
progenitors (n=5 mice/genotype) (c), and by FACS for the cell cycle status of LSK cells and 
HSCs (n=5 mice/genotype) (d) and apoptotic cells (Annexin V+) in LSK cells and HSCs 
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(n=5 mice/genotype) (e). Data are presented as mean ± SD of biological replicates. *p < 
0.05; **p < 0.01; ***p < 0.001 (Unpaired two-tailed Student’s t-test). (f) BM cells harvested 
from Slc1a5+/+ or Slc1a5−/− mice (CD45.2+) were mixed with the same number of BM cells 
isolated from BoyJ mice (CD45.1+) and transplanted into lethally irradiated BoyJ recipients 
(n=9 mice/genotype). Test cell reconstitution in the whole cell population of the PB was 
determined by FACS analyses at the indicated time points. Data are presented as mean ± SD 
of biological replicates. ***p < 0.001 (Unpaired two-tailed Student’s t-test). (g, h) BM cells 
harvested from recipient mice 16 weeks after primary transplantation were transplanted into 
lethally irradiated secondary BoyJ recipients (n=10 mice/genotype). Test cell reconstitution 
in the PB was determined as above (g). Test cell contributions to LSK cells in the BM were 
determined 16 weeks after primary and secondary transplantation by FACS analyses (n=9 
mice/genotype) (h). Data are presented as mean ± SD of biological replicates. *p < 0.05; 
***p < 0.001 (Unpaired two-tailed Student’s t-test). (i, j) Six to eight-week-old Slc1a5+/+ 
and Slc1a5−/− mice were administrated by intraperitoneal injection one dose of 5-FU (250 
mg/kg body weight) (n=10 mice/genotype) (i) or two doses of 5-FU (150 mg/kg body 
weight) with one-week interval (n=12 mice/genotype) (j). WBC counts in the PB were 
monitored. Data are presented as mean ± SD of biological replicates. *p < 0.05; **p < 0.01; 
***p < 0.001 (Unpaired two-tailed Student’s t-test) (i). Mouse survival rates were 
documented. **p < 0.01 [Log-rank (Mantel-Cox) test] (j).
Ni et al. Page 19
Nat Metab. Author manuscript; available in PMC 2019 September 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Constitutive deletion of ASCT2 inhibits MLL-AF9-induced leukemogenesis.
Lin− cells isolated from Slc1a5−/− and Slc1a5+/+ mice were infected with MSCV-MLL-AF9-
IRES-GFP retrovirus. Infected cells were expanded, sorted, and inoculated into sublethally 
irradiated BoyJ mice as described in Methods. (a) Kaplan-Meier survival curves of the mice 
receiving MLL-AF9; Slc1a5+/+ cells (n=15 mice) or MLL-AF9; Slc1a5−/− cells (n=12 
mice). ***p < 0.001 [Log-rank (Mantel-Cox) test]. (b) GFP+ leukemic cells in the PB (n=9 
mice/genotype) were determined at the indicated time points after leukemic cell inoculation. 
Data are presented as mean ± SD of biological replicates. ***p < 0.001 (Unpaired two-tailed 
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Student’s t-test). (c-e) WBC counts in the PB (c), spleen weights (d), and GFP+ leukemic 
cells in the PB, BM and spleen (e) were determined 35 days after leukemic cell inoculation 
(n=9 mice/genotype). Data are presented as mean ± SD of biological replicates. ***p < 
0.001 (Unpaired two-tailed Student’s t-test). (f) Tissues dissected from the mice inoculated 
with MLL-AF9-tranduced Slc1a5+/+ and MLL-AF9-tranduced Slc1a5−/− cells 35 days and 
140 days after the inoculation, respectively, were processed for histopathological 
examination. Representative images from 5 mice/genotype are shown. (g) Percentages of 
apoptotic cells (Annexin V+) in GFP+ leukemic cells and GFP− normal host BM cells of the 
same recipient mice (n=6 mice/genotype) were determined by FACS 35 days after the 
inoculation. Data are presented as mean ± SD of biological replicates. ***p < 0.001; N.S., 
not significant (Unpaired two-tailed Student’s t-test). (h) BM cells isolated from MLL-AF9; 
Slc1a5+/+ and MLL-AF9; Slc1a5−/− leukemic cell recipients (n=4 mice/genotype) were 
cultured in vitro for 48 hours, Apoptotic cells in the GFP+ leukemic cell population were 
determined by FACS. Data are presented as mean ± SD of biological replicates. *p < 0.05 
(Unpaired two-tailed Student’s t-test).
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Figure 3. Induced deletion of ASCT2 suppresses established leukemia induced by MLL-AF9.
Lin− cells isolated from Slc1a5fl/flMx1-Cre and Slc1a5+/+Mx1-Cre mice (without pI-pC 
treatment) were infected with MSCV-MLL-AF9-IRES-GFP retrovirus. Infected cells were 
expanded, sorted, and inoculated into sublethally irradiated BoyJ mice as described in 
Methods. Two weeks later, recipient mice were administrated with pI-pC to delete Slc1a5 
(Slc1a5Δ/Δ). (a) Kaplan-Meier survival curves of the mice inoculated with MLL-AF9; 
Slc1a5+/+ cells (n=15 mice) and MLL-AF9; Slc1a5Δ/Δ cells (n=11 mice). ***p < 0.001 
[Log-rank (Mantel-Cox) test]. (b) GFP+ leukemic cells in the PB (n=9 mice/genotype) were 
determined at the indicated time points after the inoculation. Data are presented as mean ± 
SD of biological replicates. ***p < 0.001 (Unpaired two-tailed Student’s t-test). (c-e) WBC 
counts in the PB (c), spleen weights (d), and GFP+ leukemic cells in the PB, BM, and spleen 
(e) were determined 35 days after the inoculation (n=9 mice/genotype). Data are presented 
as mean ± SD of biological replicates. ***p < 0.001 (Unpaired two-tailed Student’s t-test). 
(f) Tissues dissected from the recipients inoculated with MLL-AF9; Slc1a5+/+ or MLL-AF9; 
Slc1a5Δ/Δ cells 35 days and 140 days after the inoculation, respectively, were processed for 
histopathological examination. Representative images from 5 mice/genotype are shown. (g) 
Percentages of apoptotic cells (Annexin V+) in GFP+ leukemic cells and GFP− normal host 
BM cells of the same recipient mice (n=6 mice/genotype) were determined by FACS 35 
days after the inoculation. Data are presented as mean ± SD of biological replicates. **p < 
0.01; N.S., not significant (Unpaired two-tailed Student’s t-test).
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Figure 4. Constitutive deletion of ASCT2 inhibits Pten-loss-evoked leukemogenesis.
Six to eight-week-old Ptenfl/flMx1-Cre; Slc1a5+/+ mice (PtenΔ/Δ; Slc1a5+/+) and 
Ptenfl/flMx1-Cre; Slc1a5−/− mice (PtenΔ/Δ; Slc1a5−/−) were generated and administered pI-
pC to induce Pten deletion. (a) Kaplan–Meier survival curves of Pten+/+; Slc1a5+/+ (n=10), 
Pten+/+; Slc1a5−/− (n=10), PtenΔ/Δ; Slc1a5+/+ (n=9), and PtenΔ/Δ; Slc1a5−/− (n=12) mice. 
***p < 0.001 [Log-rank (Mantel-Cox) test]. (b-d) WBC counts in the PB (n=6 mice/
genotype) (b), total numbers of splenocytes (n=6 mice/genotype) (c), and Mac-1+ myeloid 
cells in the PB, spleen, and BM (n=9 mice/genotype) (d) were determined at 45 days after 
pI-pC administration. Data are presented as mean ± SD of biological replicates. **p < 0.01 
(Unpaired two-tailed Student’s t-test). (e) Tissues dissected from the mice were processed 
for histopathological examination 45 days after pI-pC treatment. Representative images from 
5 mice/genotype are shown.
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Figure 5. Deletion of ASCT2 decreases mitochondrial metabolism, induces cell cycle arrest and 
apoptosis in Pten deficient leukemic cells.
Lin− cells were isolated from 6–8 week-old Ptenfl/flMx1-Cre; Slc1a5−/− (PtenΔ/Δ; Slc1a5−/−) 
and Ptenfl/flMx1-Cre (PtenΔ/Δ; Slc1a5+/+) mice (n=6 mice/genotype) 10 days following pI-
pC administration. Oxygen consumption rates (OCRs) (a) and extracellular acidification 
rates (ECARs) (b) of these live cells were measured in the presence of the mitochondrial 
inhibitor oligomycin, the uncoupling agent FCCP, and the respiratory chain inhibitor 
rotenone. Summarized OCR and ECAR data at basal levels and maximal reserve capacities 
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are shown in (c). Data are presented as mean ± SD of biological replicates. *p < 0.05; ***p 
< 0.001 (Unpaired two-tailed Student’s t-test). Cells were also analyzed for total cellular 
ATP levels (d, n=5 mice/genotype), ROS levels (e, n=3 mice/genotype), LC3-I/II levels in 
whole cell lysates (f, n=2 mice/genotype. Representative images ae shown), cell cycle 
distribution (g, n=6 mice/genotype), and apoptotic cells (Annexin V+) (h, n=7 mice/
genotype). Data are presented as mean ± SD of biological replicates. *p < 0.05; **p < 0.01; 
***p < 0.001 (Unpaired two-tailed Student’s t-test).
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Figure 6. Loss of ASCT2 generates a global effect on cellular metabolism in Pten-deficient 
leukemic cells.
(a-f) Lin− cells were isolated from 6–8 week-old Ptenfl/flMx1-Cre; Slc1a5−/− (PtenΔ/Δ; 
Slc1a5−/−) and Ptenfl/flMx1-Cre (PtenΔ/Δ; Slc1a5+/+) mice 10 days after pI-pC 
administration. Cells were processed for Gln uptake assays as described in Methods (a, n=3 
mice/genotype). Data are presented as mean ± SD of biological replicates. ***p < 0.001 
(Unpaired two-tailed Student’s t-test). Intracellular α-KG (b, n=5 mice/genotype), acetyl-
CoA (c, n=5 mice/genotype), GSH/GSSG ratio (d, n=3 mice/genotype), and pyruvate (f, n=5 
mice/genotype) were determined as described in Methods. These cells were also incubated 
with 2-NBDG and analyzed for glucose uptake by FACS (e, n=3 mice/genotype). Data are 
presented as mean ± SD of biological replicates. *p < 0.05; **p < 0.01; ***p < 0.001 
(Unpaired two-tailed Student’s t-test). (g, h) Lin− cells freshly isolated from the indicated 
mice (n=3 mice/genotype) were processed for metabolomics profiling using Capillary 
Electrophoresis Time-of-Flight Mass Spectrometry (CE-TOFMS). Hierarchical cluster 
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analyses (HCA) of the metabolite levels are shown (g). Whole-cell lysates prepared from 
Lin− cells were examined by immunoblotting with anti-p-mTOR, anti-p-S6K1, p-S6, p-Akt, 
p-Erk, Pten, and ASCT2 antibodies. Densitometric data of phosphoproteins (normalized to 
pan proteins) from three independent experiments are shown on the right (h). Data are 
presented as mean ± SD of biological replicates. **p < 0.01; ***p < 0.001 (Unpaired two-
tailed Student’s t-test). (i) BM sections prepared from PtenΔ/Δ; Slc1a5−/− and PtenΔ/Δ; 
Slc1a5+/+ mice (n=4 mice/genotype) were examined by immunohistochemical staining for 
p-S6K1. Representative images from four independent experiments are shown.
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Figure 7. Cell permeable Leu analog largely reverses the effect of ASCT2 deletion on mTOR 
signaling and cell survival in leukemic cells.
(a-i) Lin− cells isolated from 6–8 week-old Ptenfl/flMx1-Cre; Slc1a5+/+ (PtenΔ/Δ; Slc1a5+/+) 
and Ptenfl/flMx1-Cre; Slc1a5−/− (PtenΔ/Δ; Slc1a5−/−) mice 10 days following pI-pC 
administration were cultured in the presence or absence of four nucleosides (5 μM) (a, n=3 
mice/genotype), NAC (2 mM) (b, n=3 mice/genotype), dimethyl-α-KG (7 mM) (c, n=3 
mice/genotype), LLME (100 μM) (e, n=4 mice/genotype), or MHY1485 (5 μM) (h, n=3 
mice/genotype) for 24 hours. Cells were then assayed for apoptotic cells (Annexin V+). (d) 
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Lin− cells isolated from PtenΔ/Δ; Slc1a5+/+ and PtenΔ/Δ; Slc1a5−/− mice were processed for 
Leu uptake assays (n=3 mice/genotype). (f, g) Lin− cells cultured in the presence or absence 
of LLME were assayed for the cell cycle status (f, n=3 mice/genotype) and senescent cells 
(g, n=3 mice/genotype). Lin− cells cultured in the presence or absence of LLME for 24 
hours were assayed by FACS for p-S6 levels (i, n=3 mice/genotype). Cells cultured in (h) 
and (i) were also assayed for p-S6 by immunoblotting. Representative results from three 
independent experiments are shown. Data are presented as mean ± SD of biological 
replicates. *p < 0.05; **p < 0.01; N.S., not significant (Unpaired two-tailed Student’s t-test). 
(j-l) MLL-AF9; Slc1a5+/+ and MLL-AF9; Slc1a5−/− leukemic cells were transplanted into 
lethally irradiated isogenic mice. Seven days after transplantation, mice were treated with 
LLME (50 mg/kg) or vehicle only by gavage (n= 5, 3, 5, and 10 mice for MLL-AF9; 
Slc1a5+/++Vehicle, MLL-AF9; Slc1a5+/++LLME, MLL-AF9-Slc1a5−/−+Vehicle, and MLL-
AF9-Slc1a5−/−+LLME groups, respectively) following the 5 days-on and 2 days-off 
schedule for 2 weeks. Kaplan-Meier survival curves of the mice were documented. ***p < 
0.001 [Log-rank (Mantel-Cox) test] (j). GFP+ leukemic cells in the PB were monitored at 
the indicated time points. Data are presented as mean ± SD of biological replicates. ***p < 
0.001 (Unpaired two-tailed Student’s t-test) (k). WBC counts in the PB were determined 21 
days after the transplantation. Data are presented as mean ± SD of biological replicates. 
***p < 0.001 (Unpaired two-tailed Student’s t-test) (l). (m-o) BM cells isolated from 
PtenΔ/Δ; Slc1a5−/− mice 10 days following pI-pC administration were transplanted into 
lethally irradiated isogenic mice. Three weeks after transplantation, mice were treated with 
LLME (50 mg/kg) or vehicle only by gavage (n= 5 and 8 for PtenΔ/Δ; Slc1a5−/−+Vehicle and 
PtenΔ/Δ; Slc1a5−/− +LLME groups, respectively) following the 5 days-on and 2 days-off 
schedule for 3 weeks. Kaplan-Meier survival curves of the mice were documented. *p < 0.01 
[Log-rank (Mantel-Cox) test] (m). Mac-1+ cells in the PB were monitored at the indicated 
time points. Data are presented as mean ± SD of biological replicates. ***p < 0.001 
(Unpaired two-tailed Student’s t-test) (n). WBC counts in the PB were determined 60 days 
after the transplantation. Data are presented as mean ± SD of biological replicates. ***p < 
0.001 (Unpaired two-tailed Student’s t-test) (o).
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Figure 8. Pharmacological inhibition of ASCT2 suppresses leukemia development in xenograft 
models of human AML.
Human primary AML cells from 6 patients and healthy BM cells from 4 individuals were 
treated with GPNA (1 mM) or vehicle control (DMSO) in triplicates. (a, b) Cell viability 
was determined at the indicated time points. Data are presented as mean ± SD of triplicates 
for each individual patient sample (a). Apoptotic cells (Annexin V+) were assayed by FACS 
analyses 24 hours later. Data are presented as mean ± SD of all patient samples. *p < 0.05 
(Unpaired two-tailed Student’s t-test) (b). (c, d) Human primary AML cells were inoculated 
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into six to eight-week-old NSG mice (1×106 cells/ mouse). Once AML was established 
(hCD45+ cells became detectable), mice were treated with intraperitoneal injections of 
GPNA (20 mg/day/kg body weight) (n=6 mice) or vehicle (n=5 mice) for 4 weeks. Mice 
were then sacrificed. Spleen (c) and liver (d) weights were determined. Data are presented as 
mean ± SD of biological replicates. ***p < 0.001 (Unpaired two-tailed Student’s t-test). (e, 
f) Percentages of human CD34+ leukemic cells (n=8 mice/group) and frequencies of 
apoptotic cells in human CD34+ leukemic cells (n=5 mice/group) in the PB (e) and BM (f) 
were determined. Data are presented as mean ± SD of biological replicates. **p < 0.01; 
***p < 0.001 (Unpaired two-tailed Student’s t-test).
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